IntrinsicIntrinsic
← All summaries

GP-Act III Acquisition Corp.

GPAT
Financials & Chart →

Business Summary

GP-Act III Acquisition Corp. (the "Company") is a blank check company, incorporated on November 23, 2020, in the Cayman Islands, with the sole purpose of effecting a business combination such as a merger, share exchange, asset acquisition, share purchase, reorganization, or similar transaction with one or more businesses . The Company has no operating history or revenues to date, and its activities since inception through December 31, 2025, have been limited to its formation, preparation for its Initial Public Offering (IPO), and the subsequent search for a prospective initial business combination target . The Company's management team intends to leverage its established global relationships, sector expertise, and active management and operating experience to identify, acquire, and operate a business or businesses .

The Company's core business model is that of a Special Purpose Acquisition Company (SPAC), which involves raising capital through an IPO to acquire an existing private company, thereby taking it public. The Company generates non-operating income from interest earned on the proceeds held in its Trust Account . Its primary "customers" are its public shareholders who invest in the Units, Class A ordinary shares, and redeemable warrants, with the expectation of participating in a successful business combination. The Company aims to acquire a target business with a fair market value of at least 80% of the net assets held in the Trust Account (excluding deferred underwriting commissions) at the time of the agreement .

The Company's capital structure consists of Units, Class A ordinary shares, Class B ordinary shares, and redeemable warrants. Each Unit, sold at $10.00 per Unit in the IPO, consists of one Class A ordinary share and one-half of one redeemable warrant . Each whole warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share . As of March 26, 2026, there were 28,750,000 Class A ordinary shares and 7,187,500 Class B ordinary shares issued and outstanding. Additionally, 7,000,000 private placement warrants were sold at $1.00 per warrant to Sponsor HoldCo and Cantor Fitzgerald & Co. .

For the fiscal year ended December 31, 2025, the Company reported a net income of $11,891,655 , compared to $8,671,665 for the year ended December 31, 2024. This income primarily consisted of interest earned on marketable securities held in the Trust Account, which amounted to $12,443,573 in 2025 and $9,236,638 in 2024. General and administrative expenses were $551,918 in 2025, a decrease from $564,973 in 2024. Basic and diluted net income per ordinary share for both Class A and Class B shares was $0.33 in 2025, a slight decrease from $0.34 in 2024. As of December 31, 2025, the Company had cash of $112,660 and marketable securities held in the Trust Account of $309,180,211 , which included approximately $21,680,211 of interest income. Total liabilities were $14,672,112 as of December 31, 2025, including a deferred underwriting fee payable of $13,687,500 and promissory notes to related parties totaling $400,000 .

The Company's financial position as of December 31, 2025, shows a working capital deficit of $446,501 . Cash used in operating activities for the year ended December 31, 2025, was $372,225 , compared to $584,718 in 2024. The Company's IPO generated gross proceeds of $287,500,000 , with $287,500,000 placed in the Trust Account. Transaction costs amounted to $20,269,166 , including a $5,000,000 cash underwriting fee and $13,687,500 in deferred underwriting fees.

During the year, the Company engaged ING Bank N.V., London branch, to provide advisory services in connection with a proposed business combination, with a success fee payable upon completion . The Company also incurred $60,000 in administrative and support services fees to an affiliate of GP Sponsor in 2025, up from $37,500 in 2024.

Business Outlook

The Company's primary objective for the upcoming period is to complete an initial business combination with one or more target businesses . The Company has a deadline of May 13, 2026 , which is 24 months from the closing of its Initial Public Offering, to consummate a business combination . If a business combination is not completed by this date, the Company will cease all operations except for winding up, redeem 100% of its outstanding Public Shares at a per-share price equal to the aggregate amount then on deposit in the Trust Account (less up to $100,000 of interest for dissolution expenses and net of taxes payable), and then liquidate and dissolve .

The Company intends to focus on high-potential businesses based in the United States with an enterprise valuation between $1.0 billion and $5.0 billion . The strategy is to acquire a target business that demonstrates strong demand for its products or services, operates in market verticals or geographies with limited competition, or is demonstrably ahead of its competition through differentiated technology, business model, or brand . The management team plans to leverage its expertise in growing successful companies, its ability to complement and support strong executive teams, its structuring and capital markets knowledge, and its differentiated sourcing capabilities and industry access . The Company also aims to maximize the value of becoming a publicly traded entity for the target business, offering broader access to debt and equity providers, liquidity for employees, and expanded branding .

Operationally, the Company expects to continue incurring significant costs in pursuit of its acquisition plans . Management's plans to address capital needs include potential loans from its co-sponsors or their affiliates, though these are not obligatory . The Company's cash of $112,660 as of December 31, 2025, is intended to primarily identify and evaluate target businesses, perform due diligence, cover travel expenses, review corporate documents, structure and negotiate business combinations, and pay for directors and officers liability insurance premiums . The Company's audit committee will review all payments made to Sponsor HoldCo, co-sponsors, directors, officers, or their affiliates on a quarterly basis to determine which expenses will be reimbursed .

Planned capital allocation includes using substantially all funds held in the Trust Account, including interest earned (less permitted withdrawals and deferred underwriting discounts and commissions), to complete the initial business combination . If capital stock or debt is used as consideration, remaining proceeds in the Trust Account will be used as working capital for the target business's operations, other acquisitions, and growth strategies . The deferred underwriting fee of $13,687,500 will become payable to the underwriter only upon the successful completion of an initial business combination . Up to $1,500,000 of working capital loans from related parties may be convertible into warrants at $1.00 per warrant at the lender's option .

Risk Factors

The Company faces significant risks, primarily stemming from its status as a blank check company with no operating history or revenues, making its ability to achieve its business objective of completing an initial business combination uncertain. A critical risk is the deadline of May 13, 2026 , to complete a business combination; failure to do so will result in liquidation, where public shareholders may receive only approximately $10.00 per share , or less, and warrants will expire worthless . Geopolitical conditions, including the Russia-Ukraine conflict and tensions in the Middle East, and U.S. policy changes, could adversely affect the search for a target business and its operations . Intense competition from other entities, including private investors and other blank check companies, for attractive target businesses may increase acquisition costs or lead to an inability to find a suitable target . The Company's financial resources are relatively limited compared to many competitors, potentially hindering its ability to acquire sizable targets . There is also a risk that the funds available outside the Trust Account, which were approximately $900,000 initially, may be insufficient to operate for the full 24 months, and affiliates are not obligated to provide future loans . If third parties bring claims against the Company, the proceeds in the Trust Account could be reduced, leading to a per-share redemption amount less than $10.00 . Conflicts of interest may arise due to the financial incentives of co-sponsors, officers, and directors, who own founder shares purchased at a nominal price of approximately $0.004 per share , potentially influencing their decisions to complete a business combination even if it is not optimal for public shareholders . The Company may issue additional Class A ordinary shares or preference shares to complete a business combination, which could significantly dilute the equity interest of public investors . Furthermore, the Company may be deemed an investment company under the Investment Company Act, which would impose burdensome compliance requirements and restrict its activities, making it difficult to complete a business combination .

Management Priorities

Management's message to shareholders emphasizes the Company's commitment as a blank check company to identifying and executing a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses . The strategic priority is to capitalize on the management team's established global relationships, sector expertise, and active management and operating experience to identify, acquire, and operate a business or businesses that can benefit from these strengths . Management intends to focus on high-potential businesses based in the United States with an enterprise valuation between $1.0 billion and $5.0 billion . A key theme is the pursuit of companies with promising growth trajectories, sustainable competitive advantages, differentiated and disruptive qualities, strong market positions, proven management teams, opportunities for operational improvement, and the ability to scale through acquisitions and strategic transactions . Management also highlights the benefits of becoming a publicly traded entity, such as broader access to capital and enhanced branding . The Company's Chief Executive Officer, Antonio Bonchristiano, and Chief Financial Officer, Rodrigo Boscolo, along with Co-Chairmen Fersen Lamas Lambranho and Steven L. Spinner, are central to this strategy, leveraging their extensive experience in private equity, investment management, and leading multi-billion-dollar companies across various sectors .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Initial Public Offering and Private Placement
  7. [7] Item 1, Business — Initial Public Offering and Private Placement
  8. [8] Item 1, Business — Initial Public Offering and Private Placement
  9. [9] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Holders
  10. [10] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Holders
  11. [11] Item 1, Business — Initial Public Offering and Private Placement
  12. [12] Item 1, Business — Initial Public Offering and Private Placement
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  22. [22] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  23. [23] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  24. [24] Item 8, Balance Sheets
  25. [25] Item 8, Balance Sheets
  26. [26] Item 8, Balance Sheets
  27. [27] Item 8, Note 1 — Liquidity and Going Concern
  28. [28] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  29. [29] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  30. [30] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  31. [31] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  32. [32] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  33. [33] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  34. [34] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  35. [35] Item 6, Note 6 — Advisory Services Agreement
  36. [36] Item 13, Certain Relationships and Related Transactions, and Director Independence — Administrative Services Agreement
  37. [37] Item 13, Certain Relationships and Related Transactions, and Director Independence — Administrative Services Agreement
  38. [38] Item 1, Business — Overview
  39. [39] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  40. [40] Item 1, Business — Overview
  41. [41] Item 1, Business — Overview
  42. [42] Item 1, Business — Market Opportunity and Business Strategy
  43. [43] Item 1, Business — Market Opportunity and Business Strategy
  44. [44] Item 1, Business — Market Opportunity and Business Strategy
  45. [45] Item 1, Business — Market Opportunity and Business Strategy
  46. [46] Item 7, MD&A — Overview
  47. [47] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  48. [48] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  49. [49] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  50. [50] Item 13, Certain Relationships and Related Transactions, and Director Independence — General and Administrative Services
  51. [51] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  52. [52] Item 7, MD&A — Liquidity, Capital Resources and Going Concern
  53. [53] Item 7, MD&A — Contractual Obligations
  54. [54] Item 7, MD&A — Contractual Obligations
  55. [55] Item 13, Certain Relationships and Related Transactions, and Director Independence — Related Party Loans
  56. [56] Item 13, Certain Relationships and Related Transactions, and Director Independence — Related Party Loans
  57. [57] Item 13, Certain Relationships and Related Transactions, and Director Independence — Related Party Loans
  58. [58] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  59. [59] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  60. [60] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  61. [61] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  62. [62] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  63. [63] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  64. [64] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  65. [65] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  66. [66] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  67. [67] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  68. [68] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  69. [69] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  70. [70] Item 1A, Risk Factors — Risks Relating to Our Search for, and Consummation of, or Inability to Consummate, a Business Combination
  71. [71] Item 1, Business — Overview
  72. [72] Item 1, Business — Overview
  73. [73] Item 1, Business — Market Opportunity and Business Strategy
  74. [74] Item 1, Business — Business Combination Criteria
  75. [75] Item 1, Business — Market Opportunity and Business Strategy
  76. [76] Item 10, Directors, Executive Officers and Corporate Governance

Analysis on 5/21/2026